MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$2,564K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Non-cash interest expense
Stock-based compensation
Change in fair value of warrant ...
Others
Negative Cash Flow Breakdown
Net loss
Effect of exchange rate changes ...
Tax credit receivable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-3,405
-2,750
-3,373
-2,806
Depreciation and amortization
34
-26
8
-21
Intangible asset impairment
-
-
0
0
Common stock issued for services
-100
-
-100
-50
Stock-based compensation
188
160
47
132
Unrealized foreign exchange gains
0
0
-1,251
0
Non-cash interest expense
790
96
19
74
Change in fair value of warrant and derivative liabilities
128
0
0
0
Deferred income taxes
-
-
0
0
Other current assets
-47
-157
152
-3
Unearned revenue
-
-
0
-
Tax credit receivable
228
216
-796
53
Prepaid expenses
-124
1,391
314
439
Accounts payable
-122
-47
-1,572
-3
Accrued expenses and other liabilities
-220
-476
-53
-324
Income taxes payable
0
0
0
0
Net cash used in operating activities
-2,564
-4,493
-3,243
-3,410
Proceeds from issuance of convertible redeemable series a preferred stock
-
-
0
0
Purchase of property and equipment
0
64
8
-
Redemption of convertible redeemable series a preferred stock
-
-
0
0
Net cash used in investing activities
0
-64
-8
-
Proceeds from convertible promissory notes and accrued interest, net of discount
-
-
-
0
Proceeds from 3i promissory notes
-
-
0
-
Repayment of 3i debt
-
-
0
0
Proceeds from atm sales of common stock, net of issuance costs
0
0
0
0
Net proceeds from sale of common stock and pre-funded warrant issuance
0
2
244
2,451
Proceeds from promissory notes
0
20,000
-
-
Common stock repurchase
0
262
484
141
Net cash provided by financing activities
0
19,740
-240
2,310
Net increase in cash and cash equivalents
-
15,183
-3,491
-1,100
Effect of exchange rate changes on cash and cash equivalents
-267
1,891
-
-1,949
Net increase in cash, cash equivalents, and restricted cash
12,294
-
-
-
Cash, cash equivalents, and restricted cash, beginning of period
29,812
14,687
16,895
19,533
Cash, cash equivalents, and restricted cash, end of period
26,981
-
-
-
Cash and cash equivalents
16,982
-
-
-
Restricted cash
9,999
-
-
-
Total cash and cash equivalents and restricted cash as presented in the condensed consolidated balance sheet
26,981
29,812
14,687
16,895
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
something is missing
$15,125K
Net increase in
cash, cash...
$12,294K
Canceled cashflow
$2,831K
Non-cash interest
expense
$790K
(758.70%↑ Y/Y)
Stock-based compensation
$188K
(-37.95%↓ Y/Y)
Change in fair value of
warrant and derivative...
$128K
(12900.00%↑ Y/Y)
Prepaid expenses
-$124K
(-114.59%↓ Y/Y)
Common stock issued for
services
-$100K
(-100.00%↓ Y/Y)
Other current assets
-$47K
(-4800.00%↓ Y/Y)
Depreciation and
amortization
$34K
(47.83%↑ Y/Y)
Net cash used in
operating activities
-$2,564K
(68.61%↑ Y/Y)
Effect of exchange rate
changes on cash and cash...
-$267K
Canceled cashflow
$1,411K
Net loss
-$3,405K
(32.60%↑ Y/Y)
Tax credit
receivable
$228K
(-72.82%↓ Y/Y)
Accrued expenses and
other liabilities
-$220K
(90.53%↑ Y/Y)
Accounts payable
-$122K
(-127.98%↓ Y/Y)
Buy us a coffee
Allarity Therapeutics, Inc. (ALLR)
Allarity Therapeutics, Inc. (ALLR)